06-Oct-2021 | Market Research Store
Prostate cancer is the most common form of cancer occurring in males. Being malignant, this typecanmetastasize and invade the surrounding tissue slowly. However, it is quite hard to diagnose.Despite themedical field is progressing at a phenomenal rate,no effective treatment againstprostate cancer is developed yet to curb the mortality rate associated with this cancer type.
To improve the pre-existing treatment of prostate cancer, the London Institute of Cancer Research has collaborated with The Royal Marsden NHS Foundation Trust to develop a novel therapy known as Lu-PSMA-617. The drug is believed to be a breakthrough in prostate cancer treatment as mentioned by Professor Ken Herman.This innovative drug expanded the surface area of the tumor cells, which helps in their destruction. The eradication of these nasty cells is done by targeting the molecule PSMA present around the infected region in the body. The research involved monitoring 831 patients, who weresuffering from this cancer typeto discover whether this treatment is more effective than the pre-existing treatment patterns. Ken mentioned that although the newly developed treatment includes targeting PSMA, it is still hypothetical research.Therefore, certain advancements are still required during clinical trials.
The research team mentioned that the volunteered patients were randomized into two groups. The patients in the first group were administered with standard care and those in the second group were offered Lu-PSMA-617 treatment along with standard care. They were astonished to found that the possibility of survival of patients administered with both treatment and care was considerably high.The study outcomes revealed thatthe average survival period of patients in the second group was 15.3 Months, while the patients, who belonged to the first group, survived for 11.8 Months on an average.This advancement in the prognosis of prostate cancer is being applauded byNICE and made researchers believe thatLu-PSMS-617 therapy could revolutionize prostate cancer therapy.
Read More: